On April 22, 2020, Caladrius Biosciences, Inc. (the \”Company\”) issued a press release announcing the Company\’s receipt of $10.9 million in net cash proceeds from the sale of its New Jersey net operating losses (\”NJ NOLs\”) to a qualifying and approved buyer. The sale of the NJ NOLs is part of the New Jersey Economic Development Authority\’s (\”NJEDA\”) Technology Business Tax Certificate Transfer Program. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statement and Exhibits.>

CALADRIUS BIOSCIENCES, INC. Exhibit
EX-99.1 2 ex99120200127njnol.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Caladrius Biosciences to Receive $10.9 Million of Non-DilutiveCapital Through New Jersey Technology Business Tax Certificate Transfer ProgramBASKING RIDGE,…
To view the full exhibit click here

About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)

Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.